Navellier & Associates Inc. Has $7.12 Million Position in Exelixis, Inc. $EXEL

Navellier & Associates Inc. reduced its stake in Exelixis, Inc. (NASDAQ:EXEL) by 10.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 172,314 shares of the biotechnology company’s stock after selling 19,247 shares during the quarter. Navellier & Associates Inc. owned approximately 0.06% of Exelixis worth $7,117,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Richardson Financial Services Inc. boosted its stake in shares of Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after buying an additional 292 shares during the last quarter. Root Financial Partners LLC bought a new stake in shares of Exelixis during the 3rd quarter valued at $28,000. Luminist Capital LLC boosted its position in shares of Exelixis by 2,740.0% during the 2nd quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 685 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in shares of Exelixis by 940.4% in the second quarter. Hantz Financial Services Inc. now owns 1,134 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 1,025 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Exelixis in the 2nd quarter valued at $60,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and set a $45.00 price objective on shares of Exelixis in a research report on Tuesday, October 21st. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a research note on Thursday, January 22nd. Wells Fargo & Company lowered their target price on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 21st. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Finally, Bank of America lowered shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price target on the stock. in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $46.16.

Insider Transactions at Exelixis

In other news, Director Stelios Papadopoulos sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the sale, the director directly owned 1,189,228 shares of the company’s stock, valued at $51,790,879.40. This represents a 7.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Patrick J. Haley sold 28,043 shares of the stock in a transaction on Friday, November 21st. The shares were sold at an average price of $42.58, for a total value of $1,194,070.94. Following the sale, the executive vice president owned 374,029 shares in the company, valued at $15,926,154.82. The trade was a 6.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 172,230 shares of company stock worth $7,401,923 over the last quarter. 2.85% of the stock is owned by company insiders.

Exelixis Stock Up 0.1%

NASDAQ:EXEL opened at $43.95 on Tuesday. The business’s 50-day simple moving average is $43.70 and its two-hundred day simple moving average is $40.94. The stock has a market cap of $11.78 billion, a PE ratio of 18.54, a P/E/G ratio of 0.74 and a beta of 0.42. Exelixis, Inc. has a 52 week low of $32.38 and a 52 week high of $49.62.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.